Progyny expands into menopause research, Barclays stays Hold
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Progyny will present new menopause research on October 22, 2026, extending its healthcare offerings beyond fertility into a full reproductive health continuum. Barclays maintained a Hold rating on the stock with a USD 30.00 price target. The company also cites an outlook of 1.2 million new covered lives, pairing broader commercial reach with clinical evidence for employers.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.